The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
HOME > REGULATORY
REGULATORY
- Entries into Generic Business Should Be Regulated by Law: LDP Lawmaker
August 10, 2023
- Japan Panel OKs Rollout of XBB.1.5-Based COVID Vaccines on Sept. 20
August 10, 2023
- Japan’s Pandemic Response Agency Officially Set to Launch on September 1
August 10, 2023
- Japan Sees Delay in Pilot-Based Revenue Assurance System for Antibiotics, Criteria Still Up in Air
August 9, 2023
- MHLW Panel OKs Online Sales of Behind-the-Counter Drugs, but with Pharmacists’ Online Supervision
August 9, 2023
- Approve 16 Pediatric Cancer Meds as Exceptional Step Beyond Law, Oncologist Urges
August 8, 2023
- Novartis’ siRNA Dyslipidemia Therapy and More Up for Panel Review on August 21
August 8, 2023
- MHLW Panel to Review Alzheimer’s Med Lecanemab on August 21
August 8, 2023
- Japan Adopts New Evaluation Method for Nitrosamine Impurities Risks
August 7, 2023
- Japan’s Healthcare Spending Up 11.0% in FY2021: IPSS Report
August 7, 2023
- Despite Increase in Reviewers, Japan Faces Backlog of Over 4,000 Health Damage Claims for COVID Jabs
August 4, 2023
- With Generics Now in Common Use, It’s Time for Debate on LLP Copay: Payers
August 4, 2023
- Japan to Set Up New Forum on Dementia Measures: PM
August 4, 2023
- 30% of Eligible Population Unaware of HPV Vaccine: Survey
August 4, 2023
- Payers Want Phase-Out of Medical Fee Premiums for Generic Use; HCPs Eye Change in Entry Pricing
August 3, 2023
- Chuikyo OKs Plan to Move Back Medical Fee Revisions to June from FY2024; Drug Price Updates to Remain in April
August 3, 2023
- Industry Calls for Excluding Orphan Drugs from Cost-Effectiveness Assessment
August 3, 2023
- Chuikyo Reps Criticize Manufacturers’ Price Cuts after Unprofitability Re-Pricing
August 3, 2023
- Relief Claims OK’ed for 38 More Deaths after COVID Vaccination
August 2, 2023
- Generics Panel Initiates Debate toward Proposing Stable Supply Measures, Interim Report Slated for October
August 1, 2023
ページ
PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…